NEW YORK, Sept. 23 (GenomeWeb News) - Perlegen Sciences said that Eli Lilly will increase its funding in support of the companies' ongoing pharmacogenomics research collaboration.

Under the partnership, which was struck in Dec. 2002, Perlegen is using its proprietary technology to genotype SNPs in clinical samples and discover genetic markers for Lilly.

Perlegen said that the increased funding is in addition to milestones and payments Lilly is making under the original deal.

Specific terms of the arrangement remain undisclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.